A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma

Kuruvilla, John, Song, Kevin, Mollee, Peter, Panzarella, Tony, McCrae, Jan, Nagy, Tracy, Crump, Michael and Keating, Armand (2006) A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology, 11 1: 25-29. doi:10.1080/10245330500276592

Author Kuruvilla, John
Song, Kevin
Mollee, Peter
Panzarella, Tony
McCrae, Jan
Nagy, Tracy
Crump, Michael
Keating, Armand
Title A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma
Journal name Hematology   Check publisher's open access policy
ISSN 1024-5332
Publication date 2006-02
Sub-type Article (original research)
DOI 10.1080/10245330500276592
Volume 11
Issue 1
Start page 25
End page 29
Total pages 5
Place of publication Leeds, W Yorks, United Kingdom
Publisher Maney Publishing
Language eng
Formatted abstract
Patients with Hodgkin's Lymphoma (HL) who relapse or progress after primary therapy and subsequent high dose chemotherapy with autologous stem cell transplantation (ASCT) cannot be cured with conventional treatment. We combined thalidomide (THAL), an agent with anti-angiogenic and immunomodulatory properties, with vinblastine, which is active after ASCT, to determine the objective response rate, improvement in B symptoms and toxicity in patients with refractory HD.

Patients were eligible if they HD that progressed after chemotherapy and ASCT or had declined or were ineligible for curative therapy. Treatment consisted of THAL 200mg orally given daily. After 2 weeks, VBL 6mg IV was given weekly × 6 doses on an eight-week cycle. Response and toxicity assessment occurred following each cycle.

Eleven patients were enrolled, 1 progressed within 6 days of study enrollment and was subsequently treated with alternative palliative therapy and thus 11 patients are response evaluable and 10 are evaluable for toxicity. Patient characteristics: relapsed after ASCT: 7; median number of prior chemotherapy regimens: 3 (range 1-5); median time to progression post-ASCT: 7 months (range 2-29). Four patients had a partial response to treatment (response rate 36%); two patients had stable disease. B symptoms were present at enrollment in four patients and resolved completely on treatment in two patients. Five had disease progression within 3 months of starting treatment. The median duration of response was 9 months (range 0-22 months). Toxicity was mild and limited to grade 2 neuropathy in 6 patients and grade 2 or 3 neutropenia in 4 patients.


In this small study in chemot herapy- refractory HL, THAL and VBL demonstrated encouraging activity with some durable responses and acceptable toxicity. These results suggest that chronic low dose chemotherapy combined with less toxic immunomodulatory or anti-angiogenic drugs warrants further study.
Keyword Hodgkin's lymphoma
Autologous stem cell transplantation
Complete remission
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: ERA 2012 Admin Only
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 15 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 24 Feb 2012, 12:51:51 EST by System User on behalf of Medicine - Princess Alexandra Hospital